PeptideTreatments

Bloodwork Before Starting CJC-1295

Medically Reviewed by Peptide Treatments Medical Advisory Board Medical Advisory Board

Why Baseline Bloodwork Matters for CJC-1295

CJC-1295 is a GHRH analog that activates pituitary somatotrophs to increase growth hormone secretion, which in turn drives hepatic IGF-1 production through the JAK2-STAT5b signaling cascade. This means a single compound directly modulates at least two hormonal axes — the GH/IGF-1 axis and, through downstream effects, glucose metabolism. Growth hormone is a counter-regulatory hormone to insulin: sustained GH elevation increases lipolysis and hepatic glucose output, which can shift fasting glucose and reduce insulin sensitivity over time. Without pre-protocol bloodwork, you have no way to distinguish a drug-induced change from a pre-existing condition. Baseline labs establish your individual reference point so that every retest during the protocol carries actual diagnostic value rather than floating without context.

What to Test Before Starting

Fasting Glucose is the first baseline draw to prioritize. CJC-1295 elevates GH, which antagonizes insulin action at the receptor level, promoting hepatic gluconeogenesis and reducing peripheral glucose uptake. If fasting glucose is already trending high before you start, adding a GH secretagogue will accelerate that trajectory. A baseline fasting glucose measurement gives your provider a clear pre-intervention number to compare against during monitoring.

Cortisol should be measured at baseline because the hypothalamic-pituitary-adrenal axis cross-talks with GH secretion. Elevated cortisol suppresses GH release and blunts the pituitary response to GHRH analogs, which means a high baseline cortisol could explain a poor response to CJC-1295 before you ever consider adjusting dose. Cortisol also influences glucose metabolism independently, so interpreting glucose shifts during the protocol requires knowing where cortisol started.

IGF-1 is the downstream marker of GH action and the most important single lab for tracking CJC-1295 efficacy. A baseline IGF-1 level tells you whether your GH/IGF-1 axis is already functioning within range or is suppressed, which directly informs dosing decisions and expected response magnitude. Without this number, you cannot quantify the actual impact of the protocol on your GH axis once retesting begins.

What to Retest and When

At 4 weeks, retest GH to assess whether pituitary output has responded to GHRH receptor stimulation. This early checkpoint catches non-responders before they spend additional weeks on an ineffective protocol and confirms the dose is producing the expected 2- to 10-fold increase in GH secretion documented in clinical studies.

At 8 weeks, retest IGF-1 to assess whether sustained GH elevation has translated into meaningful hepatic IGF-1 production. IGF-1 has a longer response curve than GH itself because it reflects cumulative GH signaling over weeks rather than acute pulsatile release. This same 8-week mark is the right time to retest Prolactin to assess whether pituitary function remains balanced, since GHRH receptor activation can influence adjacent pituitary cell populations.

Work with your prescribing provider to set the exact retest schedule. Individual response kinetics vary, and providers may adjust timing based on dose, formulation (DAC vs. non-DAC), and concurrent therapies.

Red Flags — When to Pause and Retest

Fasting glucose climbing above your baseline trend warrants immediate protocol review, particularly if you are concurrently using insulin or have pre-existing insulin resistance — GH-mediated glucose elevation compounds that risk. Any signs consistent with active malignancy or untreated pituitary disorders are absolute contraindications. If you are taking glucocorticoids, a blunted GH response paired with rising glucose should prompt your provider to reassess whether CJC-1295 is appropriate alongside that medication.

How This Fits Your Broader Protocol

CJC-1295 is frequently stacked with GHRPs like Ipamorelin or Hexarelin to amplify GH pulse amplitude alongside the sustained GHRH signaling. Review the full contraindication profile before combining compounds, and run any planned stack through the interaction checker to flag overlapping effects on glucose metabolism or pituitary load.